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A B S T R A C T
Background
Tuberculosis is generally curable with chemotherapy, but there is controversy in the literature about the need for surgical intervention
in the one to two per cent of people with tuberculosis of the spine.
Objectives
To compare chemotherapy plus surgery with chemotherapy alone for treating people diagnosed with active tuberculosis of the spine.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register (February 2010), CENTRAL (The Cochrane Library 2010,
Issue 1), MEDLINE (1966 to February 2010), EMBASE (1974 to February 2010), LILACS (1982 to February 2010), conference
proceedings, and reference lists. A search update in November 2012 revealed no new studies.
Selection criteria
Randomized controlled trials with at least one year follow up that compared chemotherapy plus surgery with chemotherapy alone for
treating active tuberculosis of the thoracic and/or lumbar spine.
Data collection and analysis
Two authors independently assessed trial eligibility, methodological quality, and extracted data. We analysed data using odds ratio with
95% confidence intervals.
Main results
Two randomized controlled trials (331 participants) met the inclusion criteria. They were conducted in the 1970s and 1980s with
follow-up reports available after 18 months, three years, and five years; one trial also reported 10 years follow up. Completeness of
follow up varied at the different time points, with less than 80% of participants available for analysis at several time points. There was
no statistically significant difference for any of the outcome measures: kyphosis angle, neurological deficit (none went on to develop
this), bony fusion, absence of spinal tuberculosis, death from any cause, activity level regained, change of allocated treatment, or bone
loss. Neither trial reported on pain. Of the 130 participants allocated to chemotherapy only, 12 had a neurological deficit and five
needed a decompression operation. One trial suggested that an initial kyphosis angle greater than 30° is likely to deteriorate, especially
in children.
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Authors’ conclusions
The two included trials had too few participants to be able to say whether routine surgery might help. Although current medication
and operative techniques are now far more advanced, these results indicate that routine surgery cannot be recommended unless within
the context of a large, well-conducted randomized controlled trial. Clinicians may judge that surgery may be clinically indicated in
some groups of patients. Future studies need to address these topics as well as the patient’s view of their disease and treatment.
P L A I N L A N G U A G E S U M M A R Y
Not enough evidence on the routine use of surgery in addition to drug treatment for people with tuberculosis of the spine
Spinal tuberculosis (spinal TB) occurs in about 1% to 2% of people with TB (the most common infectious disease in the world). The
disease can have a major impact on people’s lives. Nerves can be squeezed causing pain, loss of feeling, and breathing problems. It can
cause bone loss and curvature of the spine, which can lead to loss of nerve function and paralysis after some years, even if the TB
has been cured. Correcting with surgery at this point can be difficult because of the complexity of the surgery required. It has been
suggested that surgery might be undertaken at the time the TB of the spine is diagnosed and drug treatment (chemotherapy) is being
used. However, all surgery has potential adverse effects. This review of trials found there were insufficient numbers of participants in
the two trials located (331 participants) to be able to say if routine surgery early on was of overall benefit. Further trials are needed and
such trials should assess the pain that people suffer and their views of the disease and treatment.
B A C K G R O U N D
Incidence
Tuberculosis is the most common infectious disease in the world.
Every year 10 million new people are infected (WHO 2005).
While tuberculosis commonly infects the lungs, it is located in the
spine in one to two per cent of people (Watts 1996).
Pathology
Tuberculosis of the spine is potentially serious. The infection can
cause pain and destroy the bone making the vertebral bodies col-
lapse, thereby flexing the spine forward (kyphosis) (Figure 1).
Sometimes a nerve root may be compressed causing pain along the
root or deficit, but more commonly spinal cord compression may
lead to myelopathy (loss of feeling and muscle control) or para-
plegia. Even lung function may be compromised (Smith 1996).
If there is a sharp angle in the spine due to bony destruction, loss
of neurological function may manifest only after years, even if
the tuberculosis has been cured adequately (Hsu 1988; Rajeswari
1997a; Luk 1999). This is the result of chronic compression of the
spinal cord or a local reactivation. Late paraplegia due to spinal
cord compression is a major problem because an operation at this
stage is complex and prone to major complications often without
subsidence of the neurological deficit (Moon 1997). If the bone
has fully fused in a normal position after the primary illness pe-
riod, this late consequence is thought not to occur (Leong 1993).
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Figure 1. Lateral radiograph of the spine shows a kyphosis angle because two vertebral bodies were
destroyed by tuberculosis; the bodies have fused, and further deterioration of the angle is unlikely. The angle is
measured by drawing lines parallel to the healthy vertebral bodies above and below the fused bodies
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Most experts believe that a kyphosis over 30° is likely to gener-
ate back pain and to deteriorate (Kaplan 1952; Rajeswari 1997b;
Wimmer 1997; Parthasarathy 1999 (see ICMR/MRC1989)). Ver-
tebral body bone loss is a measure of destruction of the bone as
seen on lateral radiographs. It is expressed as units (U), 1.0 U
meaning a complete vertebral body and 0.0 U meaning no bone
loss; for example, if two bodies are partially destroyed, one lost
50% of its volume and the other 25%, the bone loss is 0.75 U. It
has been claimed to predict the final kyphosis angle (Rajasekaran
1987).
Diagnosis
Diagnosis of spinal tuberculosis in endemic areas is made mainly
using radiographs. Active disease is diagnosed when there is loss of
the thin cortical outline and rarefaction of the affected vertebral
bodies (MRC 1974a). Ideally there is a positive culture from the
site of the lesion.
Treatment
Tuberculosis in general is curable. The mainstay of treatment
is chemotherapy with at least isoniazid, rifampicin, and pyrazi-
namide. The American Thoracic Society recommends six months
of chemotherapy for spinal tuberculosis in adults and 12 months
in children because reliable data are lacking on shorter treatment
duration (Bass 1994). The British Thoracic Society recommends
six months of treatment irrespective of age (BTS 1998). In their
recent review of the literature, Van Loenhout-Rooyackers and col-
leagues found that six months of treatment is probably sufficient
for everyone (Van Loenhout 2002).
Goals of treatment
In tuberculosis, treatment is considered to be successful when the
person is cured, is no longer infectious, and does not suffer re-
lapse.However, some additional unique problems are encountered
in spinal tuberculosis, namely, kyphosis angle and neurological
deficit. Treatment in spinal tuberculosis is directed toward con-
trolling or correcting the kyphosis angle thereby restoring the bal-
ance of the spine, restoring normal neurology, preventing pain,
achieving early bony fusion (healing), preventing local recurrence
of spinal tuberculosis, andpreventing bone loss. Furthermore, peo-
ple need to regain their previous activity level to enable them to
resume their normal lives, school, jobs, and sports.
Human immunodeficiency virus (HIV) increases the risk of reac-
tivation of a latent focus and progression of the disease to a more
atypical and severe course. Studies directed specifically at spinal
tuberculosis and HIV conclude that good clinical outcomes can
be expected irrespective of the HIV status and the availability of
antiretroviral therapy (Leibert 1996; Govender 2000). Another
report mentions that people with HIV are not a homogeneous
group, and that results − especially complications like wound in-
fections−worsen during the end stage of the disease (Jellis 1996).
Role of surgery
There is controversy in the literature about the necessity of ad-
ditional surgical intervention to spinal tuberculosis treatments.
This difference of opinion goes back to 1960 when Hodgson and
Stock advocated surgical treatment (Hodgson 1960), and Kon-
stam and colleagues advocated conservative treatment (Konstam
1958; Konstam 1962). Conservative treatment consists of only
medication and sometimes additional non-operative measures
(physical therapy, orthosis, and bed rest). Surgery can basically be
divided into two procedures. The first is a debridement. This is
a procedure that comprises surgical removal of the infected mate-
rial. No attempt is made at stabilizing the spine. The second form,
which is more extensive, is a debridement with stabilization of
the spine (spinal reconstruction). The reconstruction has always
been performed with bone grafts. Today, countries with sufficient
resources perform stabilization using artificial materials like steel,
carbon fibre, or titanium (instrumentation).
Although randomized controlled trials investigating indications
are lacking, many authors consider the following indications for
surgical intervention: (1) neurological deficits (with an acute or
non-acute onset) caused by compression of the spinal cord; (2)
spinal instability caused by destruction or collapse of the vertebrae,
destruction of two or more vertebrae, or kyphosis of more than
30°; (3) no response to chemotherapeutic treatment; (4) non-
diagnostic biopsy; and (5) large paraspinal abscesses (Vidyasagar
1994; Chen 1995; Nussbaum 1995; Rezai 1995; Boachie-Adjei
1996; Watts 1996; Moon 1997). Some authors even advocate
surgery in mild cases of spinal tuberculosis (Leong 1993; Luk
1999; Turgut 2001).
Potential benefits of surgery are less kyphosis, immediate relief of
compressedneural tissue, quicker relief of pain, a higher percentage
of bony fusion, quicker bony fusion, less relapse, earlier return
to previous activities, and less bone loss. It may also prevent late
neurological problems due to kyphosis of the spine if fusion has
not occurred (Hsu 1988; Leong 1993).
Surgery requires expertise, good anaesthesia, and excellent peri-
operative care. It also requires hospitalization, and is expensive and
potentially dangerous. Complications can occur during the oper-
ation or postoperatively. Complications of spinal surgery can be
divided into several groups: reconstruction-related, vascular, neu-
rological, visceral, and wound-related. Reconstruction failures can
be breakage of the graft, screws and rods, loss of correction, and
failure of fusion (Jutte 2002). Vascular problems during surgery
can be massive bleeding, haematoma formation, and thromboem-
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bolism. Neurological damage of surgery can be nerve root lesion,
dura tears, spinal cord infarction, and plexus lesions. Visceral dam-
age, especially ureteric lesions, can occur. Wound infections hap-
pen in 1% to 6% of spinal surgeries (Fardon 2002). Considering
the potential complication rate, surgery should only be performed
if there is a clear benefit.
O B J E C T I V E S
To compare chemotherapy plus surgery with chemotherapy alone
for treating people diagnosed with active tuberculosis of the spine.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials with at least one year follow up after
the start of treatment.
Types of participants
People diagnosed with active tuberculosis of the thoracic and/or
lumbar spine, including the upper sacral vertebra S1 (Figure 2).
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Figure 2. Lateral drawing of the spine illustrating the various levels
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Active disease is diagnosed on the radiographs; there is loss of the







Both the intervention and control group must have received compara-
ble adequate chemotherapy regimen of at least six months. Adequate
refers to the guidelines commonly used when the trial took place.
Types of outcome measures







• Bony fusion, defined as the healing of adjacent affected
vertebral bodies. There is continuity of trabeculae (bone bars)
between the vertebral bodies and/or stout bony bridges, usually
best seen in the anteroposterior radiograph, projecting up to 2
cm wide of the vertebral bodies and showing trabecular
continuity even though the vertebrae are still separated by a small
space, often no more than a hairline.
• Absence of spinal tuberculosis.
• Deaths from any cause.
• Regained activity level, defined as the number of
participants that regained their previous activity level, which is
the ability of people to resume their normal lives, do their
previous jobs, sports, etc.
• Bone loss, defined as a measure of destruction of the bone
as seen on lateral radiographs. It is expressed as units (U), 1.0 U
being loss of a complete vertebral body and 0.0 U being no bone
loss; for example, if two bodies are partially destroyed, one lost
50% of its volume and the other 25%, the bone loss is 0.75 U.
Adverse events
Events related or probably related to the treatment having a neg-
ative effect on the well-being of the participants other than death
(reported separately); this includes surgical complications, failure
of reconstruction, paraplegia from the operation, and adverse ef-
fects of medication.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Appendix 1. Cochrane Infectious Diseases
Group Specialized Register (February 2010); Cochrane Central
Register of Controlled Trials (CENTRAL), published in The
Cochrane Library (2010, Issue 1); MEDLINE (1966 to February
2010); EMBASE (1974 to February 2010); LILACS (1982 to
February 2010). A search update was conducted on 28 November
2012.
Reference lists
We also checked the reference lists of all studies identified by the
above methods.
Data collection and analysis
Selection of studies
We scanned the results of the literature search for potentially rel-
evant trials and retrieved their full articles. We independently as-
sessed the potentially relevant trials for inclusion in the review
using an eligibility form based on the inclusion criteria. We en-
sured each trial was included only once and resolved disagreements
through discussion. The excluded studies are listed together with
the reason for excluding them in the ’Characteristics of excluded
studies’.
Data extraction and management
The first author extracted the data using a data extraction form
and entered the data into Review Manager 5. The second author
cross checked the data with the original paper. We also extracted
7Routine surgery in addition to chemotherapy for treating spinal tuberculosis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the number of participants allocated to surgery whowere not oper-
ated on, and those allocated to chemotherapy alone who received
surgery. We resolved disagreements by referring to the original pa-
per.
Data on neurology, pain, bony fusion, absence of spinal tubercu-
losis, death from any cause, activity level, and change of allocated
treatment were handled as dichotomous data. Data on angle of
kyphosis can be handled as continuous or dichotomous. Contin-
uous was preferred, but the required data on standard deviation
were not provided. We handled the data as dichotomous data in
two ways: (a) a final kyphosis angle being ≤ 30° or > 30°; and (b)
a progression ≤ 10° or > 10°.
Assessment of risk of bias in included studies
We independently assessed the methods used to generate the al-
location sequence and conceal allocation as adequate, inadequate,
or unclear according to Jüni 2001. We also assessed the inclusion
of all randomized participants in the final analysis and considered
at least 80% completeness of follow up at each time point to be
adequate. Blinding of the treating physicians was not possible at
the time of treatment or at follow up. Blinding of the assessor
of the radiographs of both trials was limited to pre-treatment in-
vestigations. At follow up, no information of the treatment given
was provided; signs can frequently be seen on radiographs after an
operation, especially after a reconstruction with a bone graft. We
resolved any disagreements through discussion.
Data synthesis
We analysed the data using ReviewManager 5.We used odds ratio
(OR) to assess all dichotomous outcome measures. We used the
fixed-effect model and presented the data with 95% confidence
intervals (CI).
R E S U L T S
Description of studies
Search results
The search strategy revealed 25 potentially relevant papers; their
reference lists revealed another three. We studied the full-text ver-
sions of all 28 papers. We excluded 21 papers (see ’Characteristics
of excluded studies’) and included seven publications reporting on
two randomized controlled trials involving 331 participants (see
’Characteristics of included studies’).
The British Medical Research Council Working Party on Tuber-
culosis of the Spine (MRC) co-ordinated both randomized con-
trolled trials, one in co-operation with the Indian Council ofMed-
ical Research (ICMR). The MRC performed a series of random-
ized controlled trials investigating the varying ways of treatment
of tuberculosis of the spine in several centres. This review includes
two of these trials: one fromBulawayo, Rhodesia (nowZimbabwe)
(MRC 1974a); and the other from Madras, India (ICMR/MRC
1989).
The different publications reported on the trials after 18 months,
three years, and five years (MRC 1974a; ICMR/MRC 1989);
ICMR/MRC 1989 also reported 10 years follow up. The results at
five years for ICMR/MRC 1989 were described in three different
papers. We used an article published by theMRC in 1999 to assess
the five year follow up of ICMR/MRC 1989 as it is the official
report of the trial and provides the most detailed information of
all three.
Participants
We have detailed the inclusion and exclusion criteria in the
’Characteristics of included studies’ and summarized the char-
acteristics of the 331 enrolled and randomized participants in
Appendix 2. Trials reported on the number of participants evalu-
able at the various times of follow up (Figure 3 and Figure 4). Both
trials included children (less than 15 years old) and adults, men
and women. The location of the spinal lesion was thoracic (T1 to
T10), thoracolumbar (T11 to L2), and/or lumbosacral (L2 to S1)
(Figure 2). A few participants had neurological deficit on entry
but all were able to walk.
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Figure 3. Participant flow in MRC 1974a
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Figure 4. Participant flow in ICMR/MRC 1989
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Interventions
MRC 1974a randomized 130 people to chemotherapy plus surgi-
cal debridement (no reconstruction) or chemotherapy alone. All
participants received p-amino salicylic acid (PAS) and isoniazid for
18months. Half of themwere randomized to receive streptomycin
as extra in the first three months. We were unable to determine
exactly which individual participants received streptomycin, but
for the purpose of this review we did not consider this a reason for
exclusion. Streptomycin is not a potent drug in the treatment of
tuberculosis and is no longer part of the recommended treatment
regimen (Bass 1994; BTS 1998).
ICMR/MRC1989 randomized 201 participants to chemotherapy
plus surgery (debridement and reconstruction with bone graft)
or to chemotherapy alone. The chemotherapy for all participants
was a six-month regimen of isoniazid and rifampicin. The trial
also included a third arm, which we had to exclude because these
participants received a different chemotherapy regimen consisting
of nine months treatment.
Outcomes
The trials reported on all the prespecified outcomemeasures except
pain.
Risk of bias in included studies
See ’Assessment of risk of bias in included studies’ for details and a
summary of the quality assessment in Appendix 3.
Themethods used to generate the allocation sequencewere unclear
in both trials, but the concealment of allocation was adequate.
Completeness of followup in theMRC 1974a trial was inadequate
after three years (72%) and five years (62%). In the ICMR/MRC
1989 trial, it was adequate at three years (83%) and five years
(82%), but inadequate at 10 years (78%).
Effects of interventions
Analysis in the two trials appeared to be by intention to treat. In the
chemotherapy group across the two trials, 12 participants had neu-
rological complications at entry to the trial: five of these required
surgery. Details on reasons behind the change of allocated treat-
ment are given in Appendix 4. In the chemotherapy plus surgery
group across the two trials, there was a problem with exposure of
the bone during operation in two participants and the procedure
was abandoned: both were treated with chemotherapy only. We
looked for a difference in the numbers of participants where their
actual treatment group was different to what they were originally
randomized to and detected no difference (Analysis 1.1).
Kyphosis angle
Both trials reported on kyphosis angle. They used two methods
to report change in the angle.
Mean increase of kyphosis angle (progression of kyphosis
angle at follow up)
Both trials reported that the mean degree of kyphosis angle was
within the same range at 18 months, three years, five years, and
10 years (Appendix 5), but we were unable to assess statistical
significance because standard deviations were not provided.
In ICMR/MRC 1989 at 10 years follow up, a kyphosis of greater
than 30° at the start of treatment deteriorated (increased) with a
mean of 10° to 30°. The investigators describe a subgroup effect for
age on kyphosis angle for the chemotherapy group: 17 participants
younger than 15 years with an initial angle greater than 30° had a
mean deterioration of 30° compared with the same treatment in
13 participants older than 15 years with angles greater than 30°
who deteriorated with a mean of 10° (P = 0.001).
Kyphosis angle: > 10° deterioration
MRC 1974a measured this at five years (65 participants) for le-
sions in the thoracic, thoracolumbar, and lumbosacral areas (T1
to S1), and ICMR/MRC 1989 measured this at three years (78
participants) and five years (79 participants) for lesions in the tho-
racic and thoracolumbar areas (T1 to L2). There was no statisti-
cally significant difference between groups at three years (78 par-
ticipants, 1 trial) or five years (144 participants, 2 trials); Analysis
1.2.
Neurological deficit
Both sets of trials reported on the neurological status of the par-
ticipants. No participants without neurological deficit on entry
developed neurological deficit. Neurological deficit was present at
entry in 23 participants and there was no statistically significant
difference at 18 months (23 participants, 2 trials), three years (23
participants, 2 trials), five years (20 participants, 2 trials), and 10
years (10 participants, 1 trial); Analysis 1.3.
Pain
Neither trial reported on pain.
Bony fusion
There was no statistically significant difference between chemo-
therapy plus surgery and chemotherapy alone on the presence of
bony fusion at 18 months (256 participants, 2 trials), three years
(247 participants, 2 trials), five years (236 participants, 2 trials),
or 10 years (156 participants, 1 trial); Analysis 1.4.
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Absence of spinal tuberculosis
There was no statistically significant difference between the in-
tervention and control at 18 months (261 participants, 2 trials),
three years (262 participants, 2 trials), five years (244 participants,
2 trials), and 10 years (156 participants, 1 trial); Analysis 1.5.
Deaths from any cause
Both sets of trials reported on deaths from any cause (details pro-
vided in Appendix 6). There was no statistically significant differ-
ence between the groups at 18 months (262 participants, 2 trials)
or three years (262 participants, 2 trials); Analysis 1.6. Follow up
at five or 10 years was impossible to assess because details on which
patient died in which group were not provided.
Regained activity level
Both sets of trials reported on activity level, but neither provided
data on the participants’ activity levels when they entered the tri-
als. Around 90% of participants in both groups had reached their
previous level of activity at 18 months follow up. One of the pre-
requisites for regaining activity level is normal neurology. There
were no statistically significant differences between the groups at
18 months (262 participants, 2 trials), three years (262 partici-
pants, 2 trials), five years (244 participants, 2 trials), or 10 years
(156 participants, 1 trial); Analysis 1.7.
Bone loss
The trials used two methods of reporting data on bone loss.
Mean change of bone loss (mean difference between loss at
entry and at follow up)
Neither trial report included standard deviations, which meant
that we were unable to assess the statistical significance of the
data on the mean bone losses. The major bone loss (vertebral
destruction) was present at the time of diagnosis; only limited
further destruction occurred during treatment and the subsequent
follow-up period (see Appendix 7).
Large change in bone loss
An unwanted result is considered when the amount of bone loss
has deteriorated greater than 0.25U.MRC 1974a reported on this
at five years (58 participants), and ICMR/MRC 1989 reported
data at three years (161 participants) and five years (150 partic-
ipants). There was no statistically significant difference at three
years (161 participants, 1 trial) or five years (220 participants, 2
trials); Analysis 1.8.
Adverse events
Adverse events were defined as events related or probably related
to the treatment having a negative effect on the well-being of
the participants other than death (reported separately). Adverse
events were not specifically reported by the trial authors, so we
analysed the text to identify them (Appendix 8). One participant
was operated on the wrong localization, there were seven graft
failures (breakage and displacement), and 28 cases of hepatitis, a
side effect of the chemotherapy.
D I S C U S S I O N
The objective of this systematic review was to compare chemo-
therapy plus surgery with chemotherapy alone for treating people
diagnosed with active tuberculosis of the thoracic and/or lumbar
spine. No statistically significant benefit of routine surgery was
found. Most participants received the treatment of the group to
which they were allocated. Reasons for changing treatment were
mainly neurological: five of 12 participants from the chemother-
apy group had surgery because of persisting or deteriorating neu-
rological deficit. Participants with neurological deficit form an in-
teresting subgroup for further studies.
Effects on the spine
The review did not demonstrate an effect of surgery on the kypho-
sis angle. The incidence of progressive kyphosis was high for all
participants, as was the kyphosis angle at the start of either treat-
ment. Many spine surgeons nowadays consider a kyphosis greater
than 30° to be unacceptably high and an indication for opera-
tive correction in the first place (Vidyasagar 1994; Chen 1995;
Nussbaum 1995; Rezai 1995; Boachie-Adjei 1996; Watts 1996;
Moon 1997). Nor did the review show a difference with respect to
bony fusion, often considered the best evidence of healing (MRC
1974a). Further deterioration of the kyphosis angle is unlikely af-
ter fusion. There was no statistically significant difference between
the two intervention groups on the presence of bony fusion at any
reported follow up. Data on the speed of bony fusion were not
provided in either trial, so differences during early phases of treat-
ment could not be assessed. Over time, bony fusion is obtained
in a high percentage of participants regardless of the way of treat-
ment. Similarly, bone loss was not influenced by treatment group.
The amount of bone is considered important for the stability of
the spine. People with a total bone loss of more than three U were
excluded, and the role of surgery in these more severe cases could
not be assessed.
Neurological deficit and mobility
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A small number of participants had a neurological deficit at entry,
and there were no statistically significant differences between the
interventions in the improvement of this deficit. Deterioration of
neurological deficit or persisting deficit with spinal cord compres-
sion can be an indication for surgery (Martini 1976; Leong 1993;
Watts 1996; Moon 1997). There was a subgroup of 12 partici-
pants from the chemotherapy only group (130) with neurological
deficit on entry; five of these 12 needed an operation to decom-
press the spinal cord.
Two studies reporting on non-surgical treatment of spinal tuber-
culosis conclude that it is successful in the majority of cases, even
in the presence of neurological deficit (Pattison 1986;Nene 2005).
However, the participants were not randomized, one of the studies
was retrospective (Nene 2005), and the follow up was 25% at five
years for the other report (Pattison 1986).
Some authors advocate the so-called ’middle path regimen’ in
which only patients with neurological deficit have operations (Tuli
1975; Jain 2004). They report good results, but there are no tri-
als comparing this regimen to purely non-surgical treatment or
routine surgical treatment. None of the participants included in
the included trials were paralysed severely enough to prevent them
from walking across a room. Therefore the role of surgery in these
more severe cases could not be assessed.
Almost all participants reached their previous activity levels at first
follow up, regardless of treatment. However, data on activity level
on entry of the study were not provided, so the actual improve-
ment could not be assessed. Furthermore, there may have been
differences in the speed of recovery. Regrettably neither trial as-
sessed this.
Deaths and adverse events
There was no statistically significant difference in the number of
deaths from any cause at 18 months or three years follow up. Be-
cause the trials did not provide details, we were unable to assess the
mortality at five or 10 years. In ICMR/MRC 1989, four partici-
pants died as a consequence of surgical procedures. The procedure
was introduced to the orthopaedic centre for this particular trial.
Because of these deaths, the investigators concluded that there are
problems in introducing a new major surgical procedure, even in
an orthopaedic centre, and suggest that in the light of the excellent
results achieved by chemotherapy alone that this procedure need
not and should not be introduced (ICMR/MRC 1989). The op-
erations with their high mortality rate (4/85) were performed be-
tween 1975 and 1978. Perioperative care has improved since, and
no deaths have been reported frommore recent series of operations
(Güven 1994; Rezai 1995; Lee 1999; Turgut 2001; Sundararaj
2003).
Most adverse events were related to surgery. In ICMR/MRC 1989,
four people died due to complications related to surgery, some
of these are preventable with modern day knowledge. There were
several problems related to the bone graft. The same trial reported
that three or more disc spaces had to be spanned in seven par-
ticipants with a kyphosis greater than 30°. All seven bone grafts
failed (breakage or displacement) and the deformity progressed.
Modern spinal instrumentation might prevent this failure.
There were no participants reportedwith cardio-respiratory failure
related to the deformity. In neither series there were participants
with late paraplegia in spite of some severe deformities. Follow up
of 10 years might not be sufficient for this late paraplegia; it may
only manifest itself after more than 15 years (Seddon 1935; Hsu
1988; Leong 1993; Luk 1999).
Limitations of the review
Follow up was inadequate for MRC 1974a at any time point and
for 10 years follow up of ICMR/MRC 1989. In both sets of trials
different techniques of surgery were used: debridement surgery
(MRC 1974a) and debridement plus reconstruction with bone
graft (ICMR/MRC 1989). As shown in the meta-analyses, there
were no statistically significant differences between these tech-
niques. Both sets of trials were performedmany years ago, between
1964 and 1969 for MRC 1974a and between 1975 and 1978 for
ICMR/MRC 1989. In recent years, new medications and better
operative techniques have been developed.
The introduction of pyrazinamide in 1978 dropped the relapse
rates for pulmonary tuberculosis from 7.8% and 20.3% to 1.4%
and 3.4% after two and five years follow up, respectively (MRC
1987). Randomized controlled trials are needed to assess this newer
medication in spinal tuberculosis.
Better techniques for correcting deformities of the spine like
kyphosis and scoliosis are continually beingdeveloped.These tech-
niques using metal or titanium screws, plates, and rods (instru-
mentation) have reported to be good at maintaining this correc-
tion (Güven 1994; Moon 1995; Rajasekaran 1998; Lee 1999;
Özdemir 2003; Sundararaj 2003). However, no randomized con-
trolled trials have been performed comparing chemotherapy alone
with chemotherapy plus surgical instrumentation, and they are un-
likely to be conducted because the main debate in spinal surgery is
now whether the instrumentation should be anterior, posterior, or
both (Güven 1994; Moon 1995; Moon 1997; Rajasekaran 1998;
Özdemir 2003; Sundararaj 2003).
Another limitation of the review is that there were no data on how
the patients found their treatment. It would be helpful if future
studies also address this point.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Two trials evaluated routine surgery in spinal tuberculosis, but
data are insufficient to be clear whether this policy is better than
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chemotherapy alone (with surgery used when clinically indicated).
These trials were performed some years ago, and current medi-
cation and operative techniques are far more advanced. However,
these results indicate that routine surgery cannot be recommended
unless within the context of a large, well-conducted randomized
controlled trial.
Clinicians may judge that surgery may be indicated in subgroups
of patients−with an initial kyphosis angle greater than 30° (espe-
cially in children) or progressive or persistent neurological deficit
with spinal cord compression despite chemotherapy − but there
are no randomized comparisons to support this.
Implications for research
Future trials need to assess routine surgery and also address sub-
groups of patients with spinal tuberculosis to establish the role
of surgery for specific indications. These trials need to be large
enough to assess outcomes properly. They need to assess pain and
the patient’s view of their disease and treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ICMR/MRC 1989
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: sealed envelopes
Blinding: assessor only
Inclusion of all randomized (enrolled) participants in the final analysis for primary outcomes:
1. Deformity: 73/130 (56%) at 3 years (73/94 available as x-rays technically inadequate or x-ray series incomplete
for 21 participants); 65/130 (50%) at 5 years (15 participants not assessed for x-rays not being available on 0 or 60
months follow up)
2. Neurology: 68% (89/130) at 3 years; 62% (80/130) at 5 years; 5 participants excluded for neurological assessment
(2 died of nontuberculous causes and 3 defaulted, all after 18 months)
Length of follow up: 5 years, with assessment at 18 months, 3 years, and 5 years
Participants Number (further details in Appendix 2): 201 enrolled and randomized
168 available for analysis at 3 years; losses to follow up due to no tuberculosis (3), refused surgery (2), considered
unfit for the anaesthetic (1), considered unfit for surgery (3), no evidence of active spinal tuberculosis on radiographs
(7), defaulted from 4 to 25 months (1), died of nontuberculous causes (6), operated at wrong level (1), missed
considerable amount (> 6 weeks) of chemotherapy (9)
164 available for analysis at 5 years; losses to follow up due to reasons detailed above (33), excluded due to death of
unrelated cause, default, or additional chemotherapy due to tuberculosis in other location (4; no details given)
156 available for analysis at 10 years; losses to follow up due to reasons detailed above during 0 to 5 years (37), and
excluded for nontuberculous death (4) or default from follow up (4)
Inclusion criteria: presence of clinical and radiographic evidence of tuberculosis of any vertebral body from the first
thoracic to the first sacral, inclusive, that is excluding cervical and sacral disease; disease was active clinically and/or
radiographically (radiographic active disease: (a) loss of the thin cortical outline and (b) rarefaction of the affected
vertebral bodies); availability for observation over a period of 3 years
Exclusion criteria: paraplegia or paraparesis severe enough to prevent walking; active tuberculosis in a lower limb
requiring rest in bed; pulmonary tuberculosis of a type considered likely to complicate the management; history of
previous antituberculosis chemotherapy for 12 months or more; serious nontuberculous disease likely to prejudice
the response to treatment or its assessment; contraindication to the methods of the treatment under comparison
Interventions 1. Chemotherapy
Adults (≥ 45 kg): daily streptomycin sulphate (1 g) by intramuscular injection for the first 3 months plus isoniazid
(300 mg) and sodium p-amino salicylic acid (PAS) (10 g), both for 18 months
Children (< 15 years) and adults (< 45 kg): daily streptomycin sulphate (20 mg/kg bodyweight) by intramuscular
injection for the first 3 months plus isoniazid (6 mg/kg bodyweight; maximum 300 mg) and sodium PAS (0.2 mg/
kg bodyweight; maximum 10 g), both for 18 months
Participants randomized to this regimen or the same regimen without the initial 3 months of streptomycin
2. Chemotherapy plus debridement surgery
Same chemotherapy regimen with debridement surgery: an operation to remove all necrotic and diseased tissue
without reconstruction
Outcomes 1. Kyphosis angle
2. Neurological deficit
3. Bony fusion
4. Absence of spinal tuberculosis
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ICMR/MRC 1989 (Continued)
5. Deaths from any cause
6. Regained activity level
7. Change of allocated treatment
Notes Location: Bulawayo, Rhodesia (now Zimbabwe)
Date: 3-year follow up in 1974; 5-year follow up in 1978
The 5-year report contains information about a study fromHong Kong performed by the same group of investigators,
the British Medical Research Council (MRC), with the same criteria; we excluded this part of the report from the
analysis because participants were not randomized between chemotherapy or chemotherapy plus surgery
MRC 1974a
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: sealed envelopes
Blinding: assessor only
Inclusion of all randomized (enrolled) participants in the final analysis for primary outcomes:
1. Deformity: 39% (79/201) at 5 years; 34% (69/201) at 10 years; not available at 3 years; lumbar lesions excluded
for deformity measurements, so total number less than 201, and, as a consequence, the percentages are higher than
39% and 34%, but exact figures cannot be reconstructed from article
2. Neurology: 80% (161/201) at 5 years; 78% (156/201) at 10 years; not available at 3 years
Length of follow up: 10 years, with assessment at 18 months, and 3, 5, and 10 years
Participants Number (further details in Appendix 2): 130 enrolled and randomized
94 available for analysis at 3 years, 36 lost to follow up due to no evidence on radiographs of tuberculosis (5),
permanent default (6), excessive interruption (17),major drug change (3 toxicity, 1 brucellosis), death nontuberculous
cause (3), admitted in error 1)
80 available for analysis at 5 years, 50 lost to follow up due to earlier exclusion (36 at 3 years), defaulted from follow
up between 3 and 5 years (6), died of unrelated cause (3), not explained (5)
Inclusion criteria: presence of clinical and radiographic evidence of tuberculosis of any vertebral body from the first
thoracic to the first sacral, inclusive, that is excluding cervical and sacral disease; disease was active clinically and/or
radiographically (radiographic active disease: (a) loss of the thin cortical outline and (b) rarefaction of the affected
vertebral bodies); availability for observation over a period of 3 years
Exclusion criteria: paraplegia or paraparesis severe enough to prevent walking; active tuberculosis in a lower limb
requiring rest in bed; pulmonary tuberculosis of a type considered likely to complicate the management; a history of
previous antituberculosis chemotherapy for 12 months or more; serious nontuberculous disease likely to prejudice
the response to treatment or its assessment; a contraindication to the methods of the treatment under comparison
Interventions 1. Chemotherapy
Isoniazid plus rifampicin (1 dose daily for 6 months)
2. Chemotherapy plus surgery
Isoniazid plus rifampicin (1 dose daily for 6 months) with an operation consisting of debridement (removal of all
necrotic and diseased tissue) and stabilization with a bone graft (reconstruction)
Not included in review because it has a different chemotherapy regimen without a comparable surgical intervention
group:
3. Chemotherapy
Isoniazid plus rifampicin (1 dose daily for 9 months)
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MRC 1974a (Continued)
Outcomes 1. Kyphosis angle
2. Neurological deficit
3. Bony fusion
4. Absence of spinal tuberculosis
5. Deaths from any cause
6. Regained activity level
7. Change of allocated treatment
Notes Location: Madras, India
Date: 3-year follow up in 1989; 5-year follow up in 1999; and 10-year follow up in 1999
The 5-year report also includes information from studies done in Hong Kong (all surgical) and Korea (all chemo-
therapy); we excluded these results from analysis because they did not randomize between chemotherapy alone and
chemotherapy plus surgery
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Jain 2004 Not randomized
Loembe 1994 Not randomized
MRC 1973a No surgical group
MRC 1973b No surgical group
MRC 1974b All participants had surgery
MRC 1976 No surgical group
MRC 1978a All participants had surgery
MRC 1982 All participants had surgery
MRC 1985 No surgical group
MRC 1986 All participants had surgery
MRC 1993 No surgical group
MRC 1998 No randomization for conservative or surgical treatment: 2 locations, Korea (all chemotherapy without surgery)
and Hong Kong (all chemotherapy plus surgery)
Rajasekaran 1998 No surgical group
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(Continued)
Rajeswari 1997b Not a randomized controlled trial, poor methodological quality, randomization method and concealment are
unclear; study reports on 33 participants of whom the first 10 were not randomized but all operated because of
participation in another trial (one of the included trials ICMR/MRC 1989); the other 23 patients were allocated
to chemotherapy only, 4 were lost to follow up for various reasons; of the 19 included in the analysis 3 were
operated for neurological deterioration
Seddon 1976 Description of several MRC studies, not a study itself
Upadhyay 1993 All participants had surgery
Upadhyay 1994a All participants had surgery
Upadhyay 1994b All participants had surgery
Upadhyay 1994c All participants had surgery
Upadhyay 1996 All participants had surgery
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D A T A A N D A N A L Y S E S
Comparison 1. Chemotherapy plus surgery versus chemotherapy alone




participants Statistical method Effect size
1 Change of allocated treatment 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 At 18 months 2 262 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.27, 2.09]
1.2 At 3 years 2 262 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.25, 1.82]
1.3 At 5 years 2 244 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.25, 1.92]
1.4 At 10 years 1 156 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.28, 3.60]
2 Clinically significant increase in
kyphosis angle
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Deterioration > 10 ° at 3
years
1 78 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.36, 2.16]
2.2 Deterioration > 10 ° at 5
years
2 144 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.54, 2.15]
3 Improvement in neurological
deficit
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 At 18 months 2 23 Odds Ratio (M-H, Fixed, 95% CI) 3.18 [0.47, 21.67]
3.2 At 3 years 2 23 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [0.33, 10.19]
3.3 At 5 years 2 20 Odds Ratio (M-H, Fixed, 95% CI) 2.14 [0.35, 13.13]
3.4 At 10 years 1 10 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 8.46]
4 Bony fusion 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 At 18 months 2 256 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.59, 1.59]
4.2 At 3 years 2 247 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.45, 1.27]
4.3 At 5 years 2 236 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.57, 2.00]
4.4 At 10 years 1 156 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.58, 2.81]
5 Absence of spinal tuberculosis 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At 18 months 2 261 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.67, 2.05]
5.2 At 3 years 2 262 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.58, 3.02]
5.3 At 5 years 2 244 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.36, 1.68]
5.4 At 10 years 1 156 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.52, 5.35]
6 Deaths from any cause 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 At 18 months 2 262 Odds Ratio (M-H, Fixed, 95% CI) 2.65 [0.60, 11.64]
6.2 At 3 years 2 262 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.42, 4.95]
7 Regained activity level 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 At 18 months 2 262 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.26, 1.66]
7.2 At 3 years 2 262 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.24, 1.50]
7.3 At 5 years 2 244 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.35, 1.85]
7.4 At 10 years 1 156 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.52, 5.35]
8 Deterioration of bone loss 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 At 3 years 1 161 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.31, 1.09]
8.2 At 5 years 2 220 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.41, 1.29]
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Analysis 1.1. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 1 Change of
allocated treatment.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 1 Change of allocated treatment
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 18 months
ICMR/MRC 1989 5/85 5/83 55.4 % 0.98 [ 0.27, 3.50 ]
MRC 1974a 2/47 4/47 44.6 % 0.48 [ 0.08, 2.74 ]
Subtotal (95% CI) 132 130 100.0 % 0.75 [ 0.27, 2.09 ]
Total events: 7 (Chemo + surgery), 9 (Chemotherapy)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
2 At 3 years
ICMR/MRC 1989 5/85 5/83 49.9 % 0.98 [ 0.27, 3.50 ]
MRC 1974a 2/47 5/47 50.1 % 0.37 [ 0.07, 2.03 ]
Subtotal (95% CI) 132 130 100.0 % 0.67 [ 0.25, 1.82 ]
Total events: 7 (Chemo + surgery), 10 (Chemotherapy)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
3 At 5 years
ICMR/MRC 1989 5/82 5/82 52.2 % 1.00 [ 0.28, 3.59 ]
MRC 1974a 2/45 4/35 47.8 % 0.36 [ 0.06, 2.09 ]
Subtotal (95% CI) 127 117 100.0 % 0.69 [ 0.25, 1.92 ]
Total events: 7 (Chemo + surgery), 9 (Chemotherapy)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
4 At 10 years
ICMR/MRC 1989 5/78 5/78 100.0 % 1.00 [ 0.28, 3.60 ]
Subtotal (95% CI) 78 78 100.0 % 1.00 [ 0.28, 3.60 ]
Total events: 5 (Chemo + surgery), 5 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.001 0.01 0.1 1 10 100 1000
Favours chemo+surg Favours chemotherapy
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Analysis 1.2. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 2 Clinically
significant increase in kyphosis angle.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 2 Clinically significant increase in kyphosis angle
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deterioration > 10 at 3 years
ICMR/MRC 1989 16/35 21/43 100.0 % 0.88 [ 0.36, 2.16 ]
Subtotal (95% CI) 35 43 100.0 % 0.88 [ 0.36, 2.16 ]
Total events: 16 (Chemo + surgery), 21 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
2 Deterioration > 10 at 5 years
ICMR/MRC 1989 13/34 17/45 57.6 % 1.02 [ 0.41, 2.55 ]
MRC 1974a 14/38 9/27 42.4 % 1.17 [ 0.41, 3.29 ]
Subtotal (95% CI) 72 72 100.0 % 1.08 [ 0.54, 2.15 ]
Total events: 27 (Chemo + surgery), 26 (Chemotherapy)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
0.01 0.1 1 10 100
Favours chemo+surg Favours chemotherapy
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Analysis 1.3. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 3
Improvement in neurological deficit.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 3 Improvement in neurological deficit
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 18 months
ICMR/MRC 1989 4/5 3/6 45.0 % 4.00 [ 0.27, 60.32 ]
MRC 1974a 5/6 4/6 55.0 % 2.50 [ 0.16, 38.60 ]
Subtotal (95% CI) 11 12 100.0 % 3.18 [ 0.47, 21.67 ]
Total events: 9 (Chemo + surgery), 7 (Chemotherapy)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 At 3 years
ICMR/MRC 1989 3/5 4/6 74.4 % 0.75 [ 0.06, 8.83 ]
MRC 1974a 5/6 3/6 25.6 % 5.00 [ 0.34, 72.77 ]
Subtotal (95% CI) 11 12 100.0 % 1.84 [ 0.33, 10.19 ]
Total events: 8 (Chemo + surgery), 7 (Chemotherapy)
Heterogeneity: Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.70 (P = 0.49)
3 At 5 years
ICMR/MRC 1989 4/5 5/5 87.3 % 0.27 [ 0.01, 8.46 ]
MRC 1974a 5/6 1/4 12.7 % 15.00 [ 0.66, 339.55 ]
Subtotal (95% CI) 11 9 100.0 % 2.14 [ 0.35, 13.13 ]
Total events: 9 (Chemo + surgery), 6 (Chemotherapy)
Heterogeneity: Chi2 = 2.88, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.82 (P = 0.41)
4 At 10 years
ICMR/MRC 1989 4/5 5/5 100.0 % 0.27 [ 0.01, 8.46 ]
Subtotal (95% CI) 5 5 100.0 % 0.27 [ 0.01, 8.46 ]
Total events: 4 (Chemo + surgery), 5 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
0.001 0.01 0.1 1 10 100 1000
Favours chemotherapy Favours chemo+surg
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Analysis 1.4. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 4 Bony
fusion.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 4 Bony fusion
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 18 months
ICMR/MRC 1989 39/81 37/82 59.6 % 1.13 [ 0.61, 2.09 ]
MRC 1974a 17/47 20/46 40.4 % 0.74 [ 0.32, 1.69 ]
Subtotal (95% CI) 128 128 100.0 % 0.97 [ 0.59, 1.59 ]
Total events: 56 (Chemo + surgery), 57 (Chemotherapy)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
2 At 3 years
ICMR/MRC 1989 51/81 52/82 57.8 % 0.98 [ 0.52, 1.85 ]
MRC 1974a 24/45 28/39 42.2 % 0.45 [ 0.18, 1.12 ]
Subtotal (95% CI) 126 121 100.0 % 0.76 [ 0.45, 1.27 ]
Total events: 75 (Chemo + surgery), 80 (Chemotherapy)
Heterogeneity: Chi2 = 1.90, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.06 (P = 0.29)
3 At 5 years
ICMR/MRC 1989 60/77 60/79 69.3 % 1.12 [ 0.53, 2.36 ]
MRC 1974a 37/45 29/35 30.7 % 0.96 [ 0.30, 3.07 ]
Subtotal (95% CI) 122 114 100.0 % 1.07 [ 0.57, 2.00 ]
Total events: 97 (Chemo + surgery), 89 (Chemotherapy)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
4 At 10 years
ICMR/MRC 1989 64/78 61/78 100.0 % 1.27 [ 0.58, 2.81 ]
Subtotal (95% CI) 78 78 100.0 % 1.27 [ 0.58, 2.81 ]
Total events: 64 (Chemo + surgery), 61 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 1.5. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 5 Absence
of spinal tuberculosis.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 5 Absence of spinal tuberculosis
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 18 months
ICMR/MRC 1989 57/85 53/83 77.8 % 1.15 [ 0.61, 2.18 ]
MRC 1974a 41/47 39/46 22.2 % 1.23 [ 0.38, 3.97 ]
Subtotal (95% CI) 132 129 100.0 % 1.17 [ 0.67, 2.05 ]
Total events: 98 (Chemo + surgery), 92 (Chemotherapy)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 At 3 years
ICMR/MRC 1989 77/85 77/83 74.7 % 0.75 [ 0.25, 2.26 ]
MRC 1974a 44/47 39/47 25.3 % 3.01 [ 0.75, 12.14 ]
Subtotal (95% CI) 132 130 100.0 % 1.32 [ 0.58, 3.02 ]
Total events: 121 (Chemo + surgery), 116 (Chemotherapy)
Heterogeneity: Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.66 (P = 0.51)
3 At 5 years
ICMR/MRC 1989 72/82 75/82 61.2 % 0.67 [ 0.24, 1.86 ]
MRC 1974a 37/45 29/35 38.8 % 0.96 [ 0.30, 3.07 ]
Subtotal (95% CI) 127 117 100.0 % 0.78 [ 0.36, 1.68 ]
Total events: 109 (Chemo + surgery), 104 (Chemotherapy)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
4 At 10 years
ICMR/MRC 1989 73/78 70/78 100.0 % 1.67 [ 0.52, 5.35 ]
Subtotal (95% CI) 78 78 100.0 % 1.67 [ 0.52, 5.35 ]
Total events: 73 (Chemo + surgery), 70 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
0.001 0.01 0.1 1 10 100 1000
Favours chemotherapy Favours chemo + surg
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Analysis 1.6. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 6 Deaths
from any cause.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 6 Deaths from any cause
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 18 months
ICMR/MRC 1989 4/85 0/83 20.0 % 9.22 [ 0.49, 174.01 ]
MRC 1974a 2/47 2/47 80.0 % 1.00 [ 0.13, 7.41 ]
Subtotal (95% CI) 132 130 100.0 % 2.65 [ 0.60, 11.64 ]
Total events: 6 (Chemo + surgery), 2 (Chemotherapy)
Heterogeneity: Chi2 = 1.60, df = 1 (P = 0.21); I2 =38%
Test for overall effect: Z = 1.29 (P = 0.20)
2 At 3 years
ICMR/MRC 1989 2/47 4/47 88.9 % 0.48 [ 0.08, 2.74 ]
MRC 1974a 4/85 0/83 11.1 % 9.22 [ 0.49, 174.01 ]
Subtotal (95% CI) 132 130 100.0 % 1.45 [ 0.42, 4.95 ]
Total events: 6 (Chemo + surgery), 4 (Chemotherapy)
Heterogeneity: Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.59 (P = 0.55)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.7. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 7 Regained
activity level.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 7 Regained activity level
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 18 months
ICMR/MRC 1989 77/85 78/83 66.5 % 0.62 [ 0.19, 1.97 ]
MRC 1974a 43/47 44/47 33.5 % 0.73 [ 0.15, 3.47 ]
Subtotal (95% CI) 132 130 100.0 % 0.66 [ 0.26, 1.66 ]
Total events: 120 (Chemo + surgery), 122 (Chemotherapy)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 At 3 years
ICMR/MRC 1989 76/85 78/83 69.1 % 0.54 [ 0.17, 1.69 ]
MRC 1974a 43/47 44/47 30.9 % 0.73 [ 0.15, 3.47 ]
Subtotal (95% CI) 132 130 100.0 % 0.60 [ 0.24, 1.50 ]
Total events: 119 (Chemo + surgery), 122 (Chemotherapy)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
3 At 5 years
ICMR/MRC 1989 74/82 77/82 59.7 % 0.60 [ 0.19, 1.92 ]
MRC 1974a 38/45 29/35 40.3 % 1.12 [ 0.34, 3.70 ]
Subtotal (95% CI) 127 117 100.0 % 0.81 [ 0.35, 1.85 ]
Total events: 112 (Chemo + surgery), 106 (Chemotherapy)
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
4 At 10 years
ICMR/MRC 1989 73/78 70/78 100.0 % 1.67 [ 0.52, 5.35 ]
Subtotal (95% CI) 78 78 100.0 % 1.67 [ 0.52, 5.35 ]
Total events: 73 (Chemo + surgery), 70 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
0.01 0.1 1 10 100
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Analysis 1.8. Comparison 1 Chemotherapy plus surgery versus chemotherapy alone, Outcome 8
Deterioration of bone loss.
Review: Routine surgery in addition to chemotherapy for treating spinal tuberculosis
Comparison: 1 Chemotherapy plus surgery versus chemotherapy alone
Outcome: 8 Deterioration of bone loss
Study or subgroup Chemo + surgery Chemotherapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 3 years
ICMR/MRC 1989 29/79 41/82 100.0 % 0.58 [ 0.31, 1.09 ]
Subtotal (95% CI) 79 82 100.0 % 0.58 [ 0.31, 1.09 ]
Total events: 29 (Chemo + surgery), 41 (Chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
2 At 5 years
ICMR/MRC 1989 25/75 37/75 90.6 % 0.51 [ 0.27, 0.99 ]
MRC 1974a 9/39 3/31 9.4 % 2.80 [ 0.69, 11.41 ]
Subtotal (95% CI) 114 106 100.0 % 0.73 [ 0.41, 1.29 ]
Total events: 34 (Chemo + surgery), 40 (Chemotherapy)
Heterogeneity: Chi2 = 4.61, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.08 (P = 0.28)
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A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies





tuberculosis spondylitis spinal tuberculosis





3 - 1 or 2 tuberculous spondylitis spinal tuberculosis Pott’s disease
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(Continued)
4 - - spinal TB spinal TB 1 or 2 or 3
5 - - Pott’s disease vertebral tuberculosis -
6 - - Pott’s paraplegia Pott’s disease -
7 - - 1 or 2 or 3 or 4 or 5 or 6 1 or 2 or 3 or 4 or 5 or 6 -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2005); upper case: MeSH or EMTREE heading; lower case: free text term.
Appendix 2. Characteristics of included participants
Characteristic MRC 1974a ICMR/MRC 1989
Number enrolled 130 201
Number available at follow up 3 years: 94 (47 in each arm)
5 years: 80 (45 in surgical arm, and 35 in
chemotherapy alone arm)
(some data available at 18 months)
3 years: 168 (85 in surgical arm, and 83 in
chemotherapy alone arm)
5 years: 164 (82 in each arm)
10 years: 156 (78 in each arm)
(some data available at 18 months)
Age Of the 94 people available for analysis at 3
years: 16 were < 15 years and 78≥ 15 years;
age range not given
Of the 168 people available for analysis at
3 years: 63 were < 15 years; 105≥ 15 years;
age range not given
Gender Of the 94 people available for analysis at 3
years 52 were male and 42 female
Not given
Number vertebrae involved 1 or 2 in 70 participants
> 2 in 24 participants
1 or 2 in 115 participants
> 2 in 53 participants
Location of lesions Thoracic (39 participants)
Thoracolumbar (10 participants)
Lumbar (45 participants)
Thoracic or thoracolumbar (84 partici-
pants)
Lumbar or lumbosacral (84 participants)
Kyphosis angle at entry 27° (40 surgical group participants)
24° (33 chemotherapy group participants)
(standard deviation not provided)
Only provided for thoracic or thoracolum-
bar localization:
29° (mean in the surgical group)
29° (mean in the chemotherapy group)
(standard deviation not provided)
> 20° in 66 of 84 patients with thoracic or
thoracolumbar localizations
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(Continued)
Mean total bone loss at start of treatment 0.8 U (treatment group)
0.7 U (control group)
(standard deviation not provided)
0.8 U (treatment group)
1.0 U (control group)
(standard deviation not provided)
Neurological deficit on entry 12/94 participants
12 had incomplete paraplegia but were able
to walk (inclusion criterion for this trial)
11/168 participants
11 had incomplete paraplegia but were able
to walk (inclusion criterion for this trial)
Appendix 3. Risk of bias (methodological quality) of included studiesa
Trial Allocation sequence generation Allocation concealment Inclusionb
MRC 1974a Unclear Adequate Kyphosis angle and neurology: inadequate at
3 and 5 years follow up
ICMR/MRC 1989 Unclear Adequate Kyphosis angle: inadequate at 3, 5, and 10
years follow up
Neurology: adequate at 3 and 5 years follow
up, and inadequate at 10 years follow up
aDetails in the ’Characteristics of included studies’.
bInclusion of all randomized (enrolled) participants in the analysis for primary outcomes.
Appendix 4. Reasons for changing allocated treatment
Trial Intervention No. participants Reason for change Details
MRC 1974a Chemotherapy plus
surgery
2 Additional treatment needed Received extra chemotherapy
for persistent sinus
Chemotherapy 3 Additional treatment needed Received extra chemotherapy
for progressive neurological
deficit
Chemotherapy 2 Randomization broken Needed decompression oper-
ation because of progressive
neurological deficit
ICMR/MRC 1989 Chemotherapy plus
surgery
1 Additional treatment needed Bone graft displaced posteri-
orly and a second operation
needed to remove the graft
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1 Additional treatment needed Developed myelopathy with
complete paralysis immedi-
ately postoperative for which
additional chemotherapy was
added in third month
Chemotherapy plus
surgery
1 Additional treatment needed Developed a sinus and graft
infection that needed a second
operation to remove graft
Chemotherapy plus
surgery
2 Randomization broken Problem with exposure of le-
sion during operation, which
had to be abandoned; both re-
ceived chemotherapy as allo-
cated
Chemotherapy 3 Randomization broken Needed decompression oper-
ation because of progressive
neurological deficit
Chemotherapy 2 Randomization broken Developed abscesses that were
treated with additional che-
motherapy
Appendix 5. Mean kyphosis angle (degrees)
MRC 1974a ICMR/MRC 1989
Chemotherapy plus
surgery
Chemotherapy alone Chemotherapy plus
surgery
Chemotherapy alone
Lesions T1 to S1 T1 to S1 T1 to L2 T1 to L2
Angle at start 27° 24° 29° 29°
Angle at 18 months 40° 30° 41° 41°
Angle at 3 years 40° 32° 41° 42°
Angle at 5 years 39° 30° 37° 40°
Angle at 10 years - - 41° 47°
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(Continued)
Increase in angle at 18
months
13° (40 participants) 6° (33 participants) 12° (34 participants) 12° (42 participants)
Increase in angle at 3
years
13° (40 participants) 8° (33 participants) 12° (34 participants) 13° (42 participants)
Increase in angle at 5
years
12° (34 participants) 6° (24 participants) 8° (34 participants) 11° (45 participants)
Increase in angle at 10
years
- - 12° (28 participants) 18° (41 participants)
Appendix 6. Deaths from any cause
Trial Time of death Cause of death Chemotherapy Group not provided
Plus surgery Alone
MRC 1974a 3 months Unknown, 60 years,
5 weeks after decom-
pression surgery for
progressive neurolog-






9 months Pneumonia and
dysentery
1 - -
11 months Undiagnosed acute
illness
- 1 -
23 months Heart failure in 24
year old
- 1 -




3 to 5 years Stomach cancer 1 - -
3 to 5 years Unknown - 1 -
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(Continued)
3 to 5 years Heart failure - 1 -





1 month Died < 24 h from
acute dilatation of
the stomach, man 60
years
1 - -













< 1 year Myocardial
infarction
- - 1
< 1 year Burn wounds - - 1
< 1 year Malignant disease - - 1
< 1 year Fall from height - - 1
1 to 2 years Encephalitis - - 1
1 to 2 years Unknown - - 1
2 to 3 years Viral infection - - 1
2 to 3 years Pyrexia of unknown
origin
- - 1
3 to 5 years Unknown,
nontuberculous
- - 5
5 to 10 years Unknown,
nontuberculous
2 2 -
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Appendix 7. Bone loss (U)
Trial Intervention Fraction loss:
start
Deterioration Total bone loss: 5 years
18 months 3 years 5 years
MRC 1974a Chemotherapy
plus surgery
0.8 0.2 0.3 0.2 1.0





0.8 0.3 0.3 0.3 1.1
Chemotherapy 0.95 0.4 0.5 0.5 1.45
Appendix 8. Adverse events
Adverse event Trial Chemotherapy
Plus surgery Alone
Operated on the wrong level
(excision of healthy bone in-
stead of diseased bone)
ICMR/MRC 1989 1 0
Cases of hepatitis “ 17 11
Graft failure by breakage or dis-
placement, in all these patients
the graft spanned more than 3
disc spaces (at 10 year follow
up)
” 7 0
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WH A T ’ S N E W
Last assessed as up-to-date: 22 October 2007.
Date Event Description
24 April 2013 New search has been performed New search conducted 28 November 2012; no new studies found.
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 1, 2006
Date Event Description
15 February 2010 New search has been performed new search conducted; no new studies found
5 November 2008 Amended Converted to new review format with minor editing.
23 May 2006 Amended 2006, Issue 3: Corrected an error in the ’Characteristics of included studies’
where the data for ’Participants’ were entered in the wrong columns
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Department for International Development (DFID), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2006, Issue 1 (first version of review): We added a new outcome, bone loss, because both trials included data on this. In our protocol,
we had stated that we would consider outcomes reported between 12 and 24 months because we did not expect to find trials that
followed participants for a longer period. Both included trials follow the participants for much longer, so we decided to report on all
outcomes reported. We modified one of the subgroup group analyses so that the cut-off age for children became 15 years old instead
of 18 years old (as stated in the protocol) because 15 years old is generally when growth stops and both trials used this age. We were
however unable to use some methods described in the protocol because there were too few included trials.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aminosalicylic Acid [therapeutic use]; Antitubercular Agents [∗therapeutic use]; Combined Modality Therapy [methods]; Isoniazid
[therapeutic use]; Kyphosis [etiology]; Randomized Controlled Trials as Topic; Rifampin [therapeutic use]; Streptomycin [therapeutic
use]; Tuberculosis, Spinal [complications; ∗drug therapy; ∗surgery]
MeSH check words
Humans
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